KWKailang Wu

Kailang Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kailang Wu has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Jianguo Wu

    State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China

    2 shared publications
  • Pin Wan

    Guangdong Provincial Key Laboratory of Virology Institute of Medical Microbiology Jinan University Guangzhou China

    2 shared publications
  • Chengliang Zhu

    Department of Clinical Laboratory, Institute of Translational Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, PR China

    1 shared publication
  • Fang Liu

    State Key Laboratory of Virology and College of Life Sciences, Wuhan University, Wuhan, 430071, China

    1 shared publication
  • Fengxia Xu

    Department of Laboratory Medicine, Gongli Hospital, Pudong, Shanghai, China

    1 shared publication
  • Ge Yang

    State Key Laboratory of Virology College of Life Sciences Wuhan University China

    1 shared publication

Latest Publications

  • Open Access

    The APC10 subunit of the anaphase‐promoting complex/cyclosome orchestrates NLRP3 inflammasome activation during the cell cycle

    by Siyu Huang, Pin Wan, Shanyu Huang, Siyu Liu, Qi Xiang, Ge Yang, Muhammad Adnan Shereen, Pan Pan, Jun Wang, Weiyong Liu, et al.

    The activation of the NLRP3 inflammasome plays a crucial role in the innate immune response. During cell division, NLRP3 inflammasome activation must be strictly controlled. In this study, we discover that the anaphase‐promoting complex subunit 10 (APC10), a substrate recognition protein of the anaphase‐promoting complex/cyclosome (APC/C), is a critical mediator of NLRP3 inflammasome activation. During interphase, APC10 interacts with NLRP3 to promote NLRP3 inflammasome activation, whereas during mitosis, APC10 disassociates from the NLRP3 inflammasome to repress inflammatory responses. This study reveals a distinct mechanism by which APC10 serves as a switch for NLRP3 inflammasome activation during the cell cycle.


  • Open Access

    Hepatitis B Virus e Antigen Activates the Suppressor of Cytokine Signaling 2 to Repress Interferon Action

    by Yi Yu, Pin Wan, Yanhua Cao, Wei Zhang, Junbo Chen, Li Tan, Yan Wang, Zhichen Sun, Qi Zhang, Yushun Wan, et al.

    Hepatitis B virus (HBV) infection causes acute hepatitis B (AHB), chronic hepatitis B (CHB), liver cirrhosis (LC), and eventually hepatocellular carcinoma (HCC). The presence of hepatitis B e antigen (HBeAg) in the serum generally indicates ongoing viral replication and disease progression. However, the mechanism by which HBeAg regulates HBV infection remains unclear. Interferons (IFNs) are pleiotropic cytokines that participate in host innate immunity. After binding to receptors, IFNs activate the JAK/STAT pathway to stimulate expression of IFN-stimulated genes (ISGs), leading to induction of antiviral responses. Here, we revealed that HBeAg represses IFN/JAK/STAT signaling to facilitate HBV replication. Initially, HBeAg stimulates the expression of suppressor of cytokine signaling 2 (SOCS2). Subsequently, SOCS2 impairs IFN/JAK/STAT signaling through reducing the stability of tyrosine kinase 2 (TYK2), downregulating the expression of type I and III IFN receptors, attenuating the phosphorylation and nucleus translocation of STAT1. Finally, SOCS2 inhibits the expression of ISGs, which leads to the repression of IFN action and facilitation of viral replication. These results demonstrate an important role of HBeAg in the regulation of IFN action, and provide a possible molecular mechanism by which HBV resists the IFN therapy and maintains persistent infection.


  • Open Access

    Hepatitis B virus inhibits apolipoprotein A5 expression through its core gene

    by Chengliang Zhu, Guosheng Gao, Hui Song, Fengxia Xu, Kailang Wu, Xinghui Liu

    Hepatitis B virus (HBV) infection causes lipid metabolism disorders. Apolipoprotein A5 (ApoA5) is a new apolipoprotein family member that plays an important role in the regulation of lipid metabolism. The present study was to investigate the impact of HBV on ApoA5 expression and its regulatory mechanism. Reverse transcription polymerase chain reaction (RT-PCR) and western blotting were used to measure ApoA5 mRNA and protein expression in HepG2 and HepG2.2.15 cells. Enzyme-linked immunosorbent assay (ELISA) was used to measure the serum ApoA5 levels in healthy individuals and HBV patients. HBV infectious clone pHBV1.3 or individual plasmids expressing the HBV genome was cotransfected with the ApoA5 promoter pGL3-Apo5-LUC plasmid into HepG2 cells to assess the luciferase activity. RT-PCR and western blotting methods were used to detect Apo5 mRNA and protein expression, respectively. The ApoA5 mRNA and protein expression levels were decreased in HepG2.2.15 cells compared with the control HepG2 cells. The serum ApoA5 levels were 196.4 ± 28.7 μg/L in the healthy individuals and 104.5 ± 18.3 μg/L in the HBV patients, statistical analysis showed that the ApoA5 levels were significantly lower in HBV patients than in the healthy individuals (P < 0.05). pHBV1.3 and its core gene inhibited ApoA5 promoter activity and mRNA and protein expression in HepG2 cells. HBV inhibits ApoA5 expression at both the transcriptional and translational levels through its core gene.